BioSpace News Archive

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced platform updates and disclosed five additional programs from its preclinical pipeline.

New CleanPlex® ACE2 & TMPRSS2 Panel Assesses Differences in Patients’ Genetic Susceptibility to COVID-19 Infection and to Developing Severe Disease

CytoSorbents Corporation and Aferetica srl, two pioneers in intensive care immunotherapy and blood purification, announce the European Union approval of Aferetica’s PerLife™ ex vivo organ perfusion system and CytoSorbents’ ECOS-300CY™ sorbent cartridge for the removal of inflammatory mediators during ex vivo organ perfusion.

Veeva Systems announced that Exact Sciences, a leading provider of cancer screening and diagnostic tests, selected Veeva Vault Clinical Suite to design and run its clinical studies.

The College of American Pathologists, the world’s largest organization for the doctors who diagnose and study disease, recognized several of its members for their dedication to and advancement of pathology and laboratory medicine.

Taysha Gene Therapies Inc. announced that it has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-102, an AAV9-based gene therapy in development for the treatment of Rett syndrome.

Orca Bio, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to Orca-T (NCT04013685). Orca-T is an investigational allogeneic, high-precision cell therapy for patients with blood cancers who are eligible for a hematopoietic (blood) stem cell transplant. In addition, Orca-T has received ODD from the FDA for enhancing cell engraftment in patients who qualify fo

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced unaudited preliminary revenue results for the third quarter ended September 30, 2020 . The Company expects to report third quarter revenue in th

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it will hold a conference call for investors on Wednesday, October 28, 2020, at 5:00 p.m. Eastern Time. During the conference call, management will review highlights from the Company’s third quarter 2020 financial results, which will be announced via press release after the close of market trading. The conference call can

Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that three clinical case reports and two animal studies of AC5 ® Advanced Wound System will be described in poster presentations at the upcoming 2020 Symposium on Advanced Wound Care (SAWC) Fall Virtual. The event will take place from November 4-6, 2020. AC5 Advanced Wound System recen